MADRIGAL PHARMACEUTICALS, INC. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $35.37 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2026-07-30
- MADRIGAL PHARMACEUTICALS, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-06-30 was $35.37M, a 40.59% increase year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-03-31 was $32.62M, a 55.84% increase year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-09-30 was $26.25M, a 46.68% increase year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-06-30 was $25.16M, a 3.09% increase year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2025 was $98.13M, a 22.85% increase from fiscal 2024.
- MADRIGAL PHARMACEUTICALS, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2024 was $79.88M, a 60.61% increase from fiscal 2023.
- MADRIGAL PHARMACEUTICALS, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2023 was $49.73M, a 57.26% increase from fiscal 2022.
- MADRIGAL PHARMACEUTICALS, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2022 was $31.63M, a 17.68% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $35.37M 10-Q · filed 2026-07-30 | $67.99M derived: sum of 2 quarters · filed 2026-07-30 | ||
| 2026-03-31 | $32.62M 10-Q · filed 2026-07-30 | |||
| 2025-12-31 | $98.13M 10-K · filed 2026-02-19 | |||
| 2025-09-30 | $26.25M 10-Q · filed 2025-11-04 | $51.41M derived: sum of 2 quarters · filed 2026-07-30 | $72.34M derived: sum of 3 quarters · filed 2026-07-30 | |
| 2025-06-30 | $25.16M 10-Q · filed 2026-07-30 | $46.09M derived: sum of 2 quarters · filed 2026-07-30 | ||
| 2025-03-31 | $20.93M 10-Q · filed 2026-07-30 | |||
| 2024-12-31 | $79.88M 10-K · filed 2026-02-19 | |||
| 2024-09-30 | $17.90M 10-Q · filed 2025-11-04 | $42.30M derived: sum of 2 quarters · filed 2025-11-04 | $62.20M derived: sum of 3 quarters · filed 2025-11-04 | |
| 2024-06-30 | $24.40M 10-Q · filed 2025-11-04 | $44.31M derived: sum of 2 quarters · filed 2025-11-04 | ||
| 2024-03-31 | $19.90M 10-Q · filed 2025-11-04 | |||
| 2023-12-31 | $49.73M 10-K · filed 2026-02-19 | |||
| 2023-09-30 | $12.66M 10-Q · filed 2024-10-31 | $23.63M derived: sum of 2 quarters · filed 2024-10-31 | $34.88M derived: sum of 3 quarters · filed 2024-10-31 | |
| 2023-06-30 | $10.97M 10-Q · filed 2024-10-31 | $22.22M derived: sum of 2 quarters · filed 2024-10-31 | ||
| 2023-03-31 | $11.25M 10-Q · filed 2024-10-31 | |||
| 2022-12-31 | $31.63M 10-K · filed 2025-02-26 | |||
| 2022-09-30 | $8.12M 10-Q · filed 2023-11-06 | $16.07M derived: sum of 2 quarters · filed 2023-11-06 | $23.54M derived: sum of 3 quarters · filed 2023-11-06 | |
| 2022-06-30 | $7.94M 10-Q · filed 2023-11-06 | $15.42M derived: sum of 2 quarters · filed 2023-11-06 | ||
| 2022-03-31 | $7.48M 10-Q · filed 2023-11-06 | |||
| 2021-12-31 | $26.87M 10-K · filed 2024-02-28 | |||
| 2021-09-30 | $6.24M 10-Q · filed 2022-11-03 | $14.42M derived: sum of 2 quarters · filed 2022-11-03 | $20.52M derived: sum of 3 quarters · filed 2022-11-03 | |
| 2021-06-30 | $8.18M 10-Q · filed 2022-11-03 | $14.28M derived: sum of 2 quarters · filed 2022-11-03 | ||
| 2021-03-31 | $6.10M 10-Q · filed 2022-11-03 | |||
| 2020-12-31 | $20.73M 10-K/A · filed 2023-03-03 | |||
| 2020-09-30 | $5.06M 10-Q · filed 2021-11-04 | $10.75M derived: sum of 2 quarters · filed 2021-11-04 | $15.60M derived: sum of 3 quarters · filed 2021-11-04 | |
| 2020-06-30 | $5.69M 10-Q · filed 2021-11-04 | $10.54M derived: sum of 2 quarters · filed 2021-11-04 | ||
| 2020-03-31 | $4.85M 10-Q · filed 2021-11-04 | |||
| 2019-12-31 | $22.76M 10-K · filed 2022-02-24 | |||
| 2019-09-30 | $4.95M 10-Q · filed 2020-11-05 | $12.71M derived: sum of 2 quarters · filed 2020-11-05 | $18.73M derived: sum of 3 quarters · filed 2020-11-05 | |
| 2019-06-30 | $7.75M 10-Q · filed 2020-11-05 | $13.78M derived: sum of 2 quarters · filed 2020-11-05 | ||
| 2019-03-31 | $6.02M 10-Q · filed 2020-11-05 | |||
| 2018-12-31 | $13.49M 10-K · filed 2021-02-25 | |||
| 2018-09-30 | $4.98M 10-Q · filed 2019-11-06 | $7.20M derived: sum of 2 quarters · filed 2019-11-06 | $8.37M derived: sum of 3 quarters · filed 2019-11-06 | |
| 2018-06-30 | $2.23M 10-Q · filed 2019-11-06 | $3.39M derived: sum of 2 quarters · filed 2019-11-06 | ||
| 2018-03-31 | $1.17M 10-Q · filed 2019-11-06 | |||
| 2017-12-31 | $3.25M 10-K · filed 2020-02-26 | |||
| 2016-12-31 | $7.93M 10-K · filed 2019-02-27 | |||
| 2015-12-31 | $4.30M 10-K · filed 2016-03-15 | |||
| 2014-12-31 | $7.43M 10-K · filed 2016-03-15 | |||
| 2013-12-31 | $6.03M 10-K · filed 2016-03-15 | |||
| 2012-12-31 | $3.32M 10-K · filed 2015-03-12 | |||
| 2011-12-31 | $3.35M 10-K · filed 2014-03-11 | |||
| 2010-12-31 | $4.05M 10-K · filed 2013-03-14 | |||
| 2009-12-31 | $4.58M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |